GlassScriptPhysician profile
Anthonia Egbedeju
NPI 1568758829
$5,189.17
in general payments reported to CMS, 2019-2025
26 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.70 · 2022: $716 · 2023: $1,391 · 2024: $2,280 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,457.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $928.84 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Astrazeneca Pharmaceuticals LP | $742.43 | 2022-2025 | Airsupra, Fasenra, Farxiga |
| Abbvie INC. | $490.19 | 2023-2025 | |
| Glaxosmithkline, LLC. | $344.82 | 2022-2025 | Shingrix, Arexvy |
| Amgen INC. | $255.37 | 2024 | Repatha, Otezla |
| Neurocrine Biosciences, INC. | $253.74 | 2023-2024 | Ingrezza |
| Coloplast Corp | $221.90 | 2023-2024 | Titan, Altis |
| Edwards Lifesciences Corporation | $152.57 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Gilead Sciences, INC. | $148.28 | 2025 | Epclusa |
| Abbott Laboratories | $144.65 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $134.90 | 2023 | Camzyos |
| Medtronic, INC. | $133.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $132.73 | 2023-2024 | |
| Axsome Therapeutics, INC. | $124.91 | 2024 | Auvelity |
| Tempus Ai, INC | $124.37 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $124.07 | 2022 | |
| Averitas Pharma INC. | $122.12 | 2024 | Qutenza |
| Novo Nordisk INC | $113.34 | 2024 | Wegovy |
| Antares Pharma, INC. | $112.63 | 2022 | |
| Corcept Therapeutics | $106.49 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $96.66 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.38 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.76 | 2022-2023 | Tradjenta, Jardiance, Synjardy |
| Eisai INC. | $23.74 | 2024 | |
| Exact Sciences Corporation | $22.39 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthonia Egbedeju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.